Vaccines in Multiple Sclerosis

Eric M.L. Williamson, Salim Chahin, Joseph R. Berger

Research output: Contribution to journalReview articlepeer-review

18 Scopus citations


Vaccinations help prevent communicable disease. To be valuable, a vaccine’s ability to prevent disease must exceed the risk of adverse effects from administration. Many vaccines present no risk of infection as they are comprised of killed or non-infectious components while other vaccines consist of live attenuated microorganisms which carry a potential risk of infection—particularly, in patients with compromised immunity. There are several unique considerations with respect to vaccination in the multiple sclerosis (MS) population. First, there has been concern that vaccination may trigger or aggravate the disease. Second, disease-modifying therapies (DMTs) employed in the treatment of MS may increase the risk of infectious complications from vaccines or alter their efficacy. Lastly, in some cases, vaccination strategies may be part of the treatment paradigm in attempts to avoid complications of therapy.

Original languageEnglish
Article number36
Pages (from-to)1-8
Number of pages8
JournalCurrent neurology and neuroscience reports
Issue number4
StatePublished - Apr 1 2016


  • Disease-modifying therapy
  • Immunity
  • Influenza
  • Multiple sclerosis
  • Vaccination
  • Varicella zoster


Dive into the research topics of 'Vaccines in Multiple Sclerosis'. Together they form a unique fingerprint.

Cite this